China
Africa
Explore chapters and articles related to this topic
Antituberculosis induced drug reaction with eosinophilia and systemic symptoms in a pediatric latent tuberculosis infection overdiagnosed as tuberculosis disease
Published in Ade Gafar Abdullah, Isma Widiaty, Cep Ubad Abdullah, Medical Technology and Environmental Health, 2020
W. Setiowulan, R. Rulandani, H.S. Rachman
Appearance of facial rash mimicking Lupus Erythematosus prompt a possible diagnosis of Drug Induced Lupus Erythematosus (DILE). Suspicion of DILE is made by finding of these conditions: one or more clinical symptoms of SLE (eg. arthralgias, butterfly rash, serositis), presence of antinuclear antibodies, no previous history of SLE, symptoms appear within 3 weeks to 2 years after drug administration, and rapid clinical improvement following discontinuation of the drug (Pramatarov 1998). Because ANA and anti-DNA test in this patient are negative, diagnosis of DILE may be excluded.
Questions and answers
Published in Swati Gupta, Alexandra Marsh, David Dunleavy, Kevin Channer, Cardiology and the Cardiovascular System on the move, 2015
Swati Gupta, Alexandra Marsh, David Dunleavy, Kevin Channer
(Drug-induced lupus erythematosus) Hydralazine is an anti-hypertensive commonly used intravenously in pre-eclampsia and eclampsia of pregnancy. This agent is known to cause drug-induced lupus erythematosus if used long-term. This form of lupus erythematosus is caused by an autoimmune reaction precipitated by hydralazine and up to 5% of patients on long-term therapy may demonstrate this side effect. Other drugs known to cause lupus erythematosus include procainamide (class Ia anti-arrhythmic) and isoniazid (antibiotic). Other side effects of hydralazine include a tachycardia in response to systemic vasodilatation.
Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis
Published in Scandinavian Journal of Gastroenterology, 2018
Masafumi Nishio, Yoshito Ishii, Yu Hashimoto, Haruka Otake, Tsuyoshi Ogashiwa, Saya Tsuda, Hisae Yasuhara, Yusuke Saigusa, Hideaki Kimura, Shin Maeda, Reiko Kunisaki
Seven adverse events occurred in seven (17%) patients. A summary of these adverse events is shown in Table 5. Most of the adverse events were infections (12%). One patient developed tuberculosis 2 months after adalimumab induction despite negative screening test results, including interferon-gamma release assay, tuberculin skin test, and chest radiograph results prior to adalimumab induction. This patient was treated with antituberculous therapy, discontinuation of adalimumab therapy, and colectomy. Another patient developed drug-induced lupus erythematosus and stopped adalimumab. No malignancy or death occurred during this study.
Systemic lupus erythematosus triggered by trimethoprim–sulfamethoxazole
Published in Scandinavian Journal of Rheumatology, 2020
Sulfonamide drugs are known to induce exacerbations in patients who have idiopathic SLE (2) and have also been implicated as a basis for drug-induced lupus erythematosus (DILE) (3). Our patient did not have a pre-existing diagnosis of SLE, then developed classic symptoms and positive anti-dsDNA and anti-Smith serologies specific for SLE after recurrent exposure to TMP-SMX (4). Although she had positive anti-histone antibodies, these can be present in more than 70% of patients with idiopathic SLE (5).
Tofacitinib‐induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis
Published in Modern Rheumatology Case Reports, 2021
Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterised by the presence of autoantibodies and immune complexes [1]. It is estimated that 10% of SLE cases are cases of drug-induced lupus erythematosus (DILE) [2].